Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2017, Article ID 7872519, 9 pages
https://doi.org/10.1155/2017/7872519
Research Article

Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors

1Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi University Hospital, Bologna, Italy
2Department of Diagnostic and Prevention Medicine, S.Orsola-Malpighi University Hospital, Bologna, Italy
3Department of Medical and Surgical Sciences, S.Orsola-Malpighi University Hospital, Bologna, Italy

Correspondence should be addressed to D. Campana; ti.obinu@anapmac.edivad

Received 13 July 2017; Accepted 24 September 2017; Published 29 October 2017

Academic Editor: Piero Chirletti

Copyright © 2017 G. Lamberti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Hallet, C. H. L. Law, M. Cukier, R. Saskin, N. Liu, and S. Singh, “Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes,” Cancer, vol. 121, no. 4, pp. 589–597, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. J. C. Yao, A. T. Phan, D. Z. Chang et al., “Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study,” Journal of Clinical Oncology, vol. 26, pp. 4311–4318, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. F. T. Bosman, F. Carneiro, R. H. Hruban, and N. D. Theise, WHO Classification of Tumours of the Digestive System, IARC, 4th edition, 2010.
  4. C. Ricci, R. Casadei, G. Taffurelli et al., “Validation of the 2010 WHO classification and a new prognostic proposal: a single centre retrospective study of well-differentiated pancreatic neuroendocrine tumours,” Pancreatology, vol. 16, pp. 403–410, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. V. Ambrosini, D. Campana, G. Polverari et al., “Prognostic value of 68Ga-DOTANOC PET/CT SUVmax in patients with neuroendocrine tumors of the pancreas,” Journal of Nuclear Medicine, vol. 56, pp. 1843–1848, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. M. V. Davi, E. Cosaro, S. Piacentini et al., “Prognostic factors in ectopic Cushing’s syndrome due to neuroendocrine tumors: a multicenter study,” European Journal of Endocrinology, vol. 176, no. 4, pp. 451–459, 2017. View at Publisher · View at Google Scholar
  7. M. E. Caplin, M. Pavel, J. B. Ćwikła et al., “Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study,” Endocrine-Related Cancer, vol. 23, pp. 191–199, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Rinke, H.-H. Müller, C. Schade-Brittinger et al., “Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group,” Journal of Clinical Oncology, vol. 27, pp. 4656–4663, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Strosberg, G. El-Haddad, E. Wolin et al., “Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors,” The New England Journal of Medicine, vol. 376, pp. 125–135, 2017. View at Publisher · View at Google Scholar
  10. H. S. Kim, H. S. Lee, and W. H. Kim, “Clinical significance of protein expression of cyclooxygenase-2 and somatostatin receptors in gastroenteropancreatic neuroendocrine tumors,” Cancer Research and Treatment, vol. 43, pp. 181–188, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. K. B. Song, S. C. Kim, J. H. Kim et al., “Prognostic value of somatostatin receptor subtypes in pancreatic neuroendocrine tumors,” Pancreas, vol. 45, pp. 187–192, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Lopez and D. Hanahan, “Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis,” Cancer Cell, vol. 1, pp. 339–353, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. U. Wulbrand, M. Wied, P. Zöfel, B. Göke, R. Arnold, and H. Fehmann, “Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours,” European Journal of Clinical Investigation, vol. 28, pp. 1038–1049, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Furukawa, M. Raffeld, C. Mateo et al., “Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases,” Clinical Cancer Research, vol. 11, pp. 3233–3242, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Tamborero, A. Gonzalez-Perez, C. Perez-Llamas et al., “Comprehensive identification of mutational cancer driver genes across 12 tumor types,” Scientific Reports, vol. 3, p. 2650, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Missiaglia, I. Dalai, S. Barbi et al., “Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway,” Journal of Clinical Oncology, vol. 28, pp. 245–255, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Kasajima, M. Pavel, S. Darb-Esfahani et al., “mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours,” Endocrine-Related Cancer, vol. 18, pp. 181–192, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. Jiao, C. Shi, B. H. Edil et al., “DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors,” Science, vol. 331, no. 6021, pp. 1199–1203, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. X. Han, Y. Ji, J. Zhao, X. Xu, and W. Lou, “Expression of PTEN and mTOR in pancreatic neuroendocrine tumors,” Tumor Biology, vol. 34, pp. 2871–2879, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. D. H. Yoon, M.-H. Ryu, Y. S. Park et al., “Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum,” British Journal of Cancer, vol. 106, pp. 1039–1044, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Komori, K. Yada, M. Ohta et al., “Mammalian target of rapamycin signaling activation patterns in pancreatic neuroendocrine tumors,” Journal of Hepato-Biliary-Pancreatic Sciences, vol. 21, pp. 288–295, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. I. Duran, J. Kortmansky, D. Singh et al., “A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas,” British Journal of Cancer, vol. 95, pp. 1148–1154, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Falconi, B. Eriksson, G. Kaltsas et al., “Vienna consensus conference participants: ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors,” Neuroendocrinology, vol. 103, pp. 153–171, 2016. View at Publisher · View at Google Scholar · View at Scopus
  24. B. Niederle, U.-F. Pape, F. Costa et al., “Vienna consensus conference participants: ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum,” Neuroendocrinology, vol. 103, pp. 125–138, 2016. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Scarpa, D. K. Chang, K. Nones et al., “Whole-genome landscape of pancreatic neuroendocrine tumours,” Nature, vol. 543, pp. 65–71, 2017. View at Publisher · View at Google Scholar
  26. J. C. Yao, M. H. Shah, T. Ito et al., “Everolimus for advanced pancreatic neuroendocrine tumors,” The New England Journal of Medicine, vol. 364, pp. 514–523, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. J. C. Yao, N. Fazio, S. Singh et al., “Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study,” Lancet, vol. 387, pp. 968–977, 2016. View at Publisher · View at Google Scholar · View at Scopus
  28. Z. R. Qian, M. Ter-Minassian, J. A. Chan et al., “Prognostic significance of MTOR pathway component expression in neuroendocrine tumors,” Journal of Clinical Oncology, vol. 31, pp. 3418–3425, 2013. View at Publisher · View at Google Scholar